What is Wedbush’s Estimate for AnaptysBio FY2029 Earnings?

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Wedbush issued their FY2029 earnings per share estimates for AnaptysBio in a note issued to investors on Monday, February 3rd. Wedbush analyst D. Nierengarten anticipates that the biotechnology company will earn ($4.04) per share for the year. Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

Several other research firms also recently weighed in on ANAB. Truist Financial reduced their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. JPMorgan Chase & Co. reduced their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Wolfe Research started coverage on AnaptysBio in a research report on Tuesday. They set an “outperform” rating and a $25.00 target price on the stock. Wells Fargo & Company reduced their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Finally, UBS Group increased their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.08.

AnaptysBio Trading Down 0.9 %

NASDAQ ANAB opened at $16.51 on Tuesday. The business’s 50-day moving average price is $17.23 and its 200 day moving average price is $26.89. AnaptysBio has a twelve month low of $12.51 and a twelve month high of $41.31. The company has a market capitalization of $502.40 million and a PE ratio of -2.72.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million.

Insider Transactions at AnaptysBio

In related news, Director Ecor1 Capital, Llc bought 6,646 shares of the stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently modified their holdings of ANAB. FMR LLC grew its stake in shares of AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after buying an additional 438,557 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of AnaptysBio in the third quarter valued at about $8,874,000. Victory Capital Management Inc. grew its stake in AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in AnaptysBio during the 3rd quarter valued at approximately $5,494,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.